Janssen-Cilag International NV, a Johnson & Johnson company, announced today that it has submitted applications to the European Medicines Agency to extend the marketing authorization application for.
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of.
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati.